St. Jude
This article was originally published in The Gray Sheet
Executive Summary
Patients enrolled in the U.S. Atrial Dynamic Overdrive Pacing Trial (ADOPT-A) are being implanted with the Integrity AFx (model 5346) AutoCapture pacing system with Dynamic Atrial Overdrive (DAO) algorithm for suppression of atrial fibrillation under an FDA investigational device exemption. The trial is designed to test whether DAO, an investigational feature, can suppress episodes of paroxysmal atrial fibrillation and includes patients with bradycardia and AF. The top-line Integrity was launched in dual-chamber (model 5342) and single-chamber (model 5142) options May 10 at a slight premium to St. Jude's Affinity pacer line. Integrity implants outside of ADOPT-A are not enabled to perform DAO, but have the capability, the company notes
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.